Know Cancer

or
forgot password

FDG-PET-Stratified R-DICEP and R-BEAM/ASCT For Diffuse Large B-Cell Lymphoma


N/A
18 Years
65 Years
Open (Enrolling)
Both
Diffuse Large B Cell Lymphoma

Thank you

Trial Information

FDG-PET-Stratified R-DICEP and R-BEAM/ASCT For Diffuse Large B-Cell Lymphoma


Inclusion Criteria:



- Age 18-65 years

- Diagnosis of Diffuse Large B-Cell Lymphoma

- Adverse Prognosis = Stage 3 or 4 and elevated LDH

- No more than one prior cycle of R-CHOP chemotherapy

- Adequate cardiac function

- No central nervous system involvement by lymphoma

Exclusion Criteria:

- Histological diagnosis other than Diffuse Large B-cell Lymphoma

- Pregnant or lactating females

- Use of other anti-cancer therapies

- Other serious illness that would compromise study participation

- Prior malignancy

- Prior stem cell transplant or radiotherapy

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Principal Investigator

Douglas Stewart, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Alberta Health Services

Authority:

Canada: Health Canada

Study ID:

0307003

NCT ID:

NCT00530179

Start Date:

July 2007

Completion Date:

Related Keywords:

  • Diffuse Large B Cell Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Positron Emission Tomography
  • CHOP Chemotherapy protocol
  • Stem Cell Transplantation
  • Fluorodeoxyglucose F18
  • Lymphoma
  • Lymphoma, B-Cell
  • Lymphoma, Large B-Cell, Diffuse

Name

Location